University of Memphis

University of Memphis Digital Commons
Electronic Theses and Dissertations
11-18-2017

Auditory Function in Patients Who Received Cranial Radiation
Therapy for Childhood Cancer
Johnnie Kramer Bass

Follow this and additional works at: https://digitalcommons.memphis.edu/etd

Recommended Citation
Bass, Johnnie Kramer, "Auditory Function in Patients Who Received Cranial Radiation Therapy for
Childhood Cancer" (2017). Electronic Theses and Dissertations. 1746.
https://digitalcommons.memphis.edu/etd/1746

This Dissertation is brought to you for free and open access by University of Memphis Digital Commons. It has
been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of University of
Memphis Digital Commons. For more information, please contact khggerty@memphis.edu.

AUDITORY FUNCTION IN PATIENTS WHO RECEIVED
CRANIAL RADIATION THERAPY FOR CHILDHOOD CANCER
by

Johnnie K. Bass

A Dissertation

Submitted in Partial Fulfillment of the

Requirements for the Degree of

Doctor of Philosophy

Major: Communication Sciences and Disorders

The University of Memphis

December 2017

Copyright © 2017 Johnnie K. Bass
All rights reserved

ii

DEDICATION

To John, my husband, my best friend, and my better half, for supporting and
loving me unconditionally and for pushing me to grow in ways I didn’t know were
possible.

To Ella and Nate, my children, for understanding when mom had homework too
and for inspiring me to be a better me. By the way, I love you more.

To Terry and Tammy Jones, my parents, for nurturing, supporting, and
understanding my love of learning. This will be your fourth college graduation to attend; I
promise this is it.

iii

ACKNOWLEDGEMENTS
Over the past six years I have received support and encouragement from a great
number of individuals. I would like to express my deepest appreciation to my committee
chairs, Drs. Shaum P. Bhagat and Lisa Lucks Mendel, who have been remarkable
mentors and colleagues; they continually encouraged and guided me through this
rewarding journey. They saw potential in me that I didn’t know was there, for which I am
grateful. I would like to thank my committee members—Drs. Gavin M. Bidelman and
Vikki G. Nolan—for their expertise, patience, and kindness and for conveying that
learning is a lifelong process. In addition, I want to thank the late Virginia Berry, who
first introduced me to Audiology and who instilled in me a lasting enthusiasm for helping
children with hearing impairment.
My PhD studies would not have been possible without the steadfast support and
collaborative effort between the University of Memphis School of Communication
Sciences and Disorders and St. Jude Children’s Research Hospital. I would like to thank
the professors, past and present, at the University of Memphis and my colleagues at St.
Jude for believing in me and paving the way to make this dream a reality. They
courageously supported my idea of pursuing a PhD while maintaining my full-time
employment at St. Jude. I have tremendous respect and gratitude for my mentors at St.
Jude: to Dr. Chiaho Hua for his willingness to share his expertise and for giving me my
first research opportunity; to Dr. Thomas Merchant for supporting my ideas and
providing opportunities to conduct my research; and to Dr. Kirsten Ness for encouraging
the idea of pursuing a PhD, tolerating my endless questions, and setting high
expectations. A special thank you is in order to Stephanie White and Skye Jones for

iv

being flexible with my work schedule, embracing my goals, listening to my frustrations,
celebrating my successes, and most importantly, reminding me that laughter is the best
medicine.
Last, but certainly not least, I would like to thank my family and friends for
tolerating my lunacy and for accepting nothing less than completion from me. None of
this would be possible without my people. You know who you are and I love you.

v

PREFACE
Chapter 2 was published as a manuscript in the Journal of Clinical Oncology. Bass
JK, Hua CH, Huang J, Onar-Thomas A, Ness KK, Jones S, White S, Bhagat SP, Chang
KW, Merchant TE. Hearing loss in patients who received cranial radiation therapy for
childhood cancer. J Clin Oncol. 2016; 34 (11): 1248-55.
Chapter 3 is in submission as a manuscript to the International Journal of
Radiation Oncology, Biology, and Physics. Its authors are Johnnie K. Bass, Jie Huang,
Chia-Ho Hua, Shaum P. Bhagat, Lisa L. Mendel, Arzu Onar-Thomas, Daniel J. Indelicato,
and Thomas E. Merchant.

vi

ABSTRACT
Bass, Johnnie K. Ph.D. The University of Memphis. December 2017. Auditory
Function in Patients Who Received Cranial Radiation Therapy for Childhood Cancer.
Major Professor: Lisa Lucks Mendel, Ph.D.
Patients treated with cranial radiation therapy (RT) are at risk for developing
sensorineural hearing loss (SNHL). The two manuscripts included in the dissertation
prospectively reported auditory outcomes in pediatric patients treated with cranial RT for
a brain tumor.
The first paper examined the incidence of SNHL in children treated with photonRT, including the onset and progression of SNHL. The study found that SNHL was
prevalent in 14% of patients with a median time from RT initiation to SNHL onset of 3.6
years. Among 29 patients with follow-up evaluations after onset, 65.5% experienced
progressive SNHL in either ear and 34.5% had no change. Younger age at RT initiation
[hazard ratio (HR): 2.32; 95% confidence interval (CI): 1.21, 4.46], higher cochlear
radiation dose (HR: 1.07; CI: 1.03, 1.11), and cerebrospinal shunting (HR: 2.02; CI: 1.07,
3.78) were associated with SNHL.
The second paper assessed auditory outcomes in patients treated with proton
radiotherapy (PRT) for craniopharyngioma, including the incidence, onset, and severity of
SNHL. Additionally, changes in hearing and cochlear function were described by
comparing distortion-product otoacoustic emission (DPOAE) levels, pure-tone
audiometric thresholds for the conventional frequency (CF: 0.25 through 8.0 kHz) and
extended high-frequency (EHF: 9.0 through 16 kHz) ranges, and speech-in-noise (SIN)
perception scores from baseline to last evaluation. The study revealed that zero of 74
evaluable patients had clinically relevant SNHL in the CF range with no decline in SIN
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perception scores (P = 0.65); 2.7% of the patients had mild SNHL in the EHF range. A
decrease in hearing was observed in 32.4% of patients in either or both the CF and EHF
ranges with a median time to onset of 24.6 months. DPOAE amplitude decreased at a
much faster rate at higher versus lower frequencies.
Overall, SNHL is a late effect of photon-RT that likely worsens over time.
Conversely, clinical SNHL in children treated with PRT for craniopharyngioma was
minimal and was observed in the EHF range only, suggesting that PRT may reduce the
risk for significant SNHL when compared to photon-RT. However, subtle decreases in
auditory function were observed, warranting long-term audiological follow-up post-RT.
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Chapter 1
General Introduction
The overall incidence rate for cancer in the United States has increased over the
past three decades in children and adolescents, yet mortality has declined by more than
50% with a five-year survival rate for most pediatric cancers approaching 80% or more.1
Although cure rates have significantly improved, survivors of childhood and adolescent
cancer remain at risk for adverse treatment-related and quality of life outcomes such as
hearing loss.
Pediatric cancers are commonly treated using a combination of surgery,
chemotherapy, and/or radiation therapy (RT). Cranial RT is an essential component of
treatment for many childhood brain tumors leading to improved survival for several
childhood malignancies. Although considerably less ototoxic than cisplatin chemotherapy,
cranial RT is still associated with high risk for sensorineural hearing loss (SNHL) when
used in isolation2-4 and even more so when administered with concurrent or adjuvant
cisplatin.5,6
Over the past few decades, advancements in radiotherapy techniques have
significantly improved treatment for cancer, particularly for head and neck tumors.
Conformal RT is superior to conventional RT and has become the standard of care in the
treatment of childhood head and neck malignancies.7 The combination of diagnostic
imaging with highly sophisticated equipment and technology used in conformal RT
modalities permit higher doses of radiation to the primary tumor site while sparing
surrounding healthy tissues, thus reducing acute and late adverse treatment effects.
Conformal RT techniques differ based on treatment modality (proton versus photons) and
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delivery including, but not limited to, three-dimensional conformal RT, intensitymodulated RT (IMRT), and proton RT (PRT).7
Three-dimensional conformal RT delivers shaped photon radiation beams of the
same strength to the tumor site from several different directions and has been the most
common approach to treating brain tumors but has also been associated with abnormalities
in growth and development,8 endocrine,9 and cognition.10,11 IMRT has been widely used
since the 1990s as a way of delivering conformal RT in a targeted manner. With IMRT,
the photon radiation beam varies in strength across the treatment area and is shaped and
distributed in various ways to deliver higher radiation doses to the primary tumor site
while lessening radiation scatter to surrounding healthy tissue.12 Despite these major
advances in RT, long-term morbidities such as SNHL,4,13 cognitive decline,14 and an
increased overall risk for chronic health conditions,15 to name a few, continue to be a
concern for survivors of childhood cancer. Permanent SNHL has been reported in up to
27% of children treated with photon-based RT in the absence of chemotherapy.4,13
Proton-based radiotherapy is a recent advance in the treatment of pediatric brain
tumors as a means to improve survival and functional outcomes. PRT uses protons rather
than photons used in standard X-ray RT, which differ mainly in the way radiation is
deposited throughout tissue. Photons distribute energy throughout the treatment path the
moment it enters the body increasing the potential for damage to healthy tissues and
organs. Conversely, protons release the majority of radiation directly in the tumor and then
stops. Protons lose very little radiation before reaching the tumor site with no radiation
distributed past the tumor. Thus, damage to surrounding, healthy tissue is minimized.12
Recent studies have demonstrated favorable early auditory outcomes in pediatric patients
treated with PRT versus photon RT for medulloblastoma16,17 and ependymoma.18
2

Although PRT produces a more delineated dose distribution that theoretically leads to
improved long-term functional outcomes, prospective clinical trials of PRT techniques are
needed and should include long-term audiologic follow-up to determine whether hearing is
preserved.
In both animals and humans, histopathological changes to the inner ear following
radiation exposure include damage to the inner and outer cochlear hair cells and
supporting cells,19,20 vascular degeneration,21 and deterioration of the basilar membrane,
spiral ligament, stria vascularis,20 spiral ganglion, and cochlear nerve.19,20 In humans, the
cochlear hair cells and stria vascularis receive the maximum damage following high-dose
RT,22 and can ultimately lead to permanent SNHL.
Radiation and SNHL exhibit a dose-response relationship; higher doses of
radiation to the cochlea increases risk for SNHL.3,4 Radiation-induced SNHL typically
manifests several years after completion of therapy, occurring on average three to five
years post-RT.2,4,5,13 Sensorineural hearing loss is more commonly detected in the higher
frequencies4,23 and can be progressive.5 Damage to the auditory nerve and central
pathways has also been reported.24
Adult patients have shown a significant risk for developing SNHL following RT;25
however, reports of age effects on radiation-induced SNHL in pediatric patients are
limited. A lower mean cochlear radiation dose of less than 35 Gy has been recommended
for pediatric patients4 compared to ≤ 45 Gy for adults26,27 to minimize the risk of longterm SNHL, suggesting that younger patients may be at higher risk for developing SNHL
at radiation doses tolerated by adults.
The long-term effects of SNHL in the developing child, particularly during critical
stages of speech and language acquisition and development, can be devastating. High3

frequency SNHL, the most common type of radiation-associated hearing loss, can interfere
with the acquisition of certain phonemes (primarily fricatives) that are critical for normal
speech and language development.28 Sensorineural hearing loss acquired during childhood
can significantly impair speech and language, educational, and psychosocial
development,29,30 particularly if SNHL goes undetected and/or untreated. Compared to
normal hearing people, individuals with hearing impairment have higher levels of stress,
depression, anxiety, somatization, and loneliness,31 reduced cognition32,33 and academic
achievement,32,34 higher unemployment rates and lower income,35 and overall poorer
quality of life.34
Even mild or unilateral hearing losses in children are associated with poorer
communication and educational outcomes. Unilateral hearing loss has been shown to
negatively impact speech and language and full intelligence quotient scores in
adolescents.36 Studies have demonstrated that academic performance is poorer among
children and adolescents with mild or unilateral hearing loss when compared to their
normal hearing peers.29,37-40 Thus, early detection and management of SNHL is critical in
mitigating these adverse outcomes. The earlier SNHL is identified and treated, the better
the outcome for language and speech development, academic achievement, and social
well-being.41-43
Although delayed onset of SNHL from cranial RT has been well documented in
the literature, reports of long-term auditory outcomes and potential risk factors for
radiation-induced SNHL among pediatric patients are limited. This dissertation research
aimed to examine the long-term impact of cranial RT on auditory function and potential
risk factors for SNHL in patients treated for childhood cancer.
This dissertation is a collection of two journal articles, one published and one
4

submitted for publication. The first paper investigated the incidence, onset, severity, and
long-term trajectory of SNHL and potential risk factors for SNHL among pediatric
patients treated with photon radiotherapy. Multivariable logistic regression and Cox
proportional hazards models with repeated measures were used to investigate potential
risk factors associated with time to SNHL. To our knowledge, the long-term trajectory of
auditory function and the effect of age on SNHL had not been previously reported in
children treated with cranial RT.
As an extension of the first paper, the second study investigated the effect of PRT
on auditory function in children diagnosed with craniopharyngioma. Specifically, the
objectives of this study were to 1) report the incidence, onset, and severity of SNHL; 2)
describe changes in hearing and cochlear function by comparing distortion-product
otoacoustic emission (DPOAE) amplitude levels, conventional frequency (CF) pure-tone
audiometric thresholds (0.25 through 8.0 kHz), and extended high-frequency (EHF) puretone audiometric thresholds (9.0 through 16.0 kHz) over time, 3) explore the potential
impact PRT has on SIN perception, and 4) identify potential risk factors associated with
decreased auditory function in children and adolescents treated with PRT for
craniopharyngioma. The McNemar’s exact test was used to compare hearing decline in the
EHF range versus the CF range. A univariable generalized estimating equation model with
repeated measures was used to investigate potential risk factors associated with decreased
hearing sensitivity. For DPOAE amplitude data analysis, mixed models for longitudinal
data (i.e., random coefficient models) were used and a random coefficient model was used
to examine SIN performance over time. Because PRT is a newer RT modality, very few
studies have reported the impact of PRT on hearing sensitivity.
Collectively, the two papers examined the effect of photon- and proton-based RT
5

on auditory function in children treated for brain cancer. This research will serve as an
important reference for the radiation-oncology and audiology fields as well as a
benchmark to be used to further improve RT modalities to reduce treatment-related
SNHL. This research will also improve early detection and intervention of SNHL by
providing a better understanding of auditory outcomes in children treated with cranial RT
and by refining the current audiological test battery to include diagnostic tests sensitive to
subtle changes in auditory function.
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Chapter 2
Hearing Loss in Patients Who Received
Cranial Radiation Therapy for Childhood Cancer
Introduction
Pediatric brain tumors are treated by surgical resection, chemotherapy, and/or
radiation therapy (RT). Although contemporary multimodality therapy is typically
effective, sensorineural hearing loss (SNHL) is a common adverse effect. Cranial RT is
less ototoxic than platinum-based chemotherapy (i.e., cisplatin), but is still associated with
high risk for SNHL,2-4 and even more so when combined with cisplatin.5,6 Risk and
severity of SNHL increases when a higher radiation dose is delivered to the temporal
bone, where otologic structures reside.2-4,25 Damage to any part of the auditory mechanism
can cause hearing loss,44 and the reported incidence of RT-induced SNHL varies (0%54%) across studies.45
RT-induced histopathologic changes to the inner ear cause SNHL. In animal
models and humans, RT-induced damage to the cochlear hair cells and supporting
cells,19,20 vascular degeneration,21 and deterioration of the basilar membrane, spiral
ligament, stria vascularis,20 spiral ganglion, and cochlear nerve19,20 have been reported.
RT-induced SNHL typically manifests several years after RT,2,4,5,13 preferentially affects
higher frequencies,4,13,23 and can be progressive.5 Damage to the auditory nerve and
central pathways has also been reported.24
Risk for SNHL in adults receiving RT is well documented,6,44-46 whereas reports in
pediatric patients or childhood cancer survivors are limited. The objectives of this study
were to report the incidence, onset, and severity of SNHL; document the trajectory of
SNHL progression; and identify potential risk factors associated with RT-induced SNHL

7

in children.
Patients and Methods
Patients
Eligible patients included 361 children enrolled in a phase II trial of conformal RT
for localized brain tumors from 1997 through 2010 who received prospective longitudinal
audiologic evaluations. Patients received no RT before enrollment. The trial was approved
by the Human Subjects Institutional Review Board at St. Jude Children’s Research
Hospital, and informed consent was obtained from all patients/guardians. Patients were
treated with photons, using forward-planned conformal RT or inversely planned intensitymodulated RT. Target volumes for RT varied according to tumor type. During this study,
the gross tumor volume included the residual tumor or postoperative tumor bed; the
clinical target volume margin included subclinical microscopic disease and was
anatomically confined, varying from 10 to 5mm beyond the gross tumor volume. The
planning target volume margin varied from 5 to 3mm and included a geometric expansion
surrounding the clinical target volume. The prescribed dose to the planning target volume
was 54 Gy (craniopharyngioma and low-grade glioma) or 54 to 59.4 Gy (ependymoma).
Fractionation was 1.8 Gy/day administered in five fractions per week. Each cochlea was
contoured within the temporal bone on computed tomography images without additional
margin (Figure 1). Because of the small size, mean dose was calculated to represent the
cochlear radiation dose (CRD). During treatment planning, efforts were made to spare the
cochlea without jeopardizing tumor coverage. Patients with the following conditions were
excluded from this analysis: exposure to platinum-based chemotherapy (n = 55),
permanent SNHL in at least one ear prior to RT (n = 36), permanent conductive hearing
loss (n = 4), and insufficient audiologic data (i.e., fewer than two evaluations or
8

incomplete testing (n = 31).

Figure 1. Computed tomography image demonstrating how the cochlea was contoured
within the temporal bone without additional margin.

Audiologic Methods
Procedures for evaluating hearing varied based on patient age, health status,
cognitive and developmental abilities, and cooperation. Otoscopy and tympanometry were
used to determine the condition of the external ear canal, tympanic membrane, and
middle-ear space. Pure-tone air-conduction thresholds were evaluated in a sound-treated
booth at 0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz in decibel hearing level (dB HL) for most
patients. Pure-tone bone-conduction thresholds were assessed at 0.25, 0.5, 1, 2, 3, and 4
kHz dB HL to establish type of hearing loss (i.e., conductive, sensorineural, or mixed).
Although behavioral audiometric testing in a sound-treated booth is the gold standard,
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assessments that did not require active participation were necessary for some patients:
tone-burst auditory brainstem response (ABR), auditory steady-state response (ASSR),
and/or distortion-product otoacoustic emissions. These tests were used in patients who
were young, had poor health, cognitive or developmental delay, or lack of cooperation.
Patients completed hearing assessments pre-RT (baseline), every 6 months for 5
years post-RT, and annually thereafter for at least 5 years. Audiologic testing was
performed by a certified, licensed audiologist. Audiometric data were assigned a grade
based on the Chang Ototoxicity Grading Scale47 (Table 1), which uses absolute-hearing
threshold levels highly correlated with recommendations for audiologic intervention (i.e.,
hearing aids, personal frequency-modulation systems). Grading was based on boneconduction thresholds or air-conduction thresholds with a normal tympanogram. SNHL
was defined as Chang grade 1a or higher. Progressive SNHL was defined as any increase
in Chang grade in either ear from SNHL onset to latest evaluation.

Table 1. Severity of Sensorineural Hearing Loss at Onset and at Last Evaluation by the
Chang Ototoxicity Grading Scale (N = 235)
Grade

Criteria

Onset (%)

Last Evaluation (%)

202 (86.0)

202 (86.0)

0

≤20 dB at 1, 2, and 4 kHz

1a

≥40 dB at 6–12 kHz

10 (4.3)

3 (1.3)

1b

>20 and <40 dB at 4 kHz

2 (0.9)

1 (0.4)

2a

≥40 dB at ≥4 kHz

3 (1.3)

1 (0.4)

2b

>20 and <40 dB at <4 kHz

12 (5.1)

9 (3.8)

3

≥40 dB at ≥2 kHz

3 (1.3)

6 (2.6)

4

≥40 dB at ≥1 kHz

3 (1.3)

13 (5.5)

Note: Sensorineural hearing threshold in decibel (dB) was assessed by bone conduction or
air conduction with normal tympanogram. The worse ear was used when a patient had an
asymmetric Chang grade.
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Statistical Analysis
Summary statistics were obtained to describe patient characteristics. The
Wilcoxon-Mann-Whitney test was used to examine if age at RT initiation differed
between patients with SNHL and those with normal hearing. Spearman rank correlations
were used to evaluate associations between age at RT initiation and CRD to each ear. The
Fisher’s exact test was used to investigate the association between age (< 3 years v ≥ 3
years) and diagnosis (infratentorial ependymoma versus others). A paired t test was used
to examine the difference in CRDs between ears. Non-parametric statistics were used
when data followed a skewed distribution as evidenced in age and diagnosis in our cohort.
Multivariable logistic regression with repeated measures was used to investigate
potential risk factors for SNHL. Kaplan-Meier methods were used to describe time to
SNHL and time to progression after SNHL diagnosis. Cox proportional hazards models
with repeated measures were used to investigate potential risk factors associated with time
to SNHL. A backward selection approach was used to identify final models. Potential
explanatory variables included age at RT initiation (< 3 years v ≥ 3 years), CRD (Gy),
sex, the presence of a cerebrospinal fluid (CSF) shunt, number of surgeries (≤ 1 v > 1),
and tumor location (supratentorial versus infratentorial). A significance level of 0.05 was
used throughout without adjusting for multiplicity. Analyses were performed using SAS
9.3 (SAS Institute, Cary, NC) and R 3.0.2 (R Core Development Team; http://www.rproject.org/).
Results
Patient Characteristics
Among 235 evaluable patients, the most common diagnoses were ependymoma,
craniopharyngioma, and juvenile pilocytic astrocytoma (Table 2). All but one patient had a
11

measurable CRD (> 0 Gy) in at least one ear. One patient received no CRD to either
cochlea and had normal hearing. Median age at RT initiation was 7.2 years (range, 1.0 to
24.4 years), and median CRDs to the left and right ears were 29.5 Gy (range, 0.0 to 61.7
Gy) and 28.8 Gy (range, 0.0 to 63.9 Gy), respectively. The median follow-up from RT
initiation to latest audiogram was 9 years (range, 0.8 to 16.0 years), with a median of 11
post-RT audiograms per patient (range, 1 to 19). Of the 235 evaluable patients, 49 (21%)
received initial ABR/ASSR evaluations with subsequent conventional audiometric
evaluations; 1 (0.4%) had distortion product otoacoustic emissions performed at baseline
with subsequent conventional audiometric evaluations, and 2 (0.9%) received an
ABR/ASSR evaluation at baseline and subsequent follow-up.
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Table 2. Patient Characteristics (N = 235)
Characteristic
Sex
Male
Female
Race
White
Non-white
Age at RT initiation (years)
< 3 years
≥ 3 years
Age at latest audiogram (years)
Time from RT initiation to latest audiogram (years)
Post-RT audiograms, No.
Shunt status
Yes
No
No. surgeries
≤1
>1
CRD (Gy)
Left ear
Right ear
Tumor Location
Infratentorial
Supratentorial
Histologic diagnosis
Ependymoma
Craniopharyngioma
Juvenile pilocytic astrocytoma

No. (%)

Median

Range

Interquartile
range

7.2

1.0–24.4

3.9–12.3

17.0
9.0
11

2.1–36.3
0.8–16.0
1–19

12.6 –21.1
6.0–11.1
7–14

29.5
28.8

0.0–61.7
0.0–63.9

17.0–44.7
15.8–42.9

119 (50.6)
116 (49.4)
194 (82.6)
41 (17.4)
43 (18.3)
192 (81.7)

76 (32.3)
159 (67.7)
157 (66.8)
78 (33.2)

86 (36.6)
149 (63.4)
92 (39.1)
73 (31.1)
37 (15.7)
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Table 2. Patient Characteristics (N = 235)
Characteristic

No. (%)

Median

Range

Interquartile
range

Anaplastic astrocytoma
7 (3.0)
Optic pathway glioma
5 (2.1)
Low-grade astrocytoma
3 (1.3)
Ganglioglioma
3 (1.3)
Oligodendroglioma
3 (1.3)
Glioblastoma multiforme
2 (0.9)
Other astroglial tumors*
10 (4.1)
Abbreviations: CRD, cochlear radiation dose; No., number of; RT, radiation therapy
*WHO I & II, central neurocytoma, choroid plexus carcinoma, malignant glial neuronal, malignant neurocytoma, neurocytoma,
pilomyxoid astrocytoma, pleomorphic xanthroastrocytoma
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SNHL Prevalence and Severity
At last evaluation, 33 patients (14%) had SNHL (four patients had a conductive
overlay but were included in the SNHL group based on bone-conduction thresholds).
Thirteen had bilateral SNHL, and 20 had unilateral SNHL. Five (2.1%) had mild SNHL
(grades 1a to 2a), and 28 (11.9%) had significant SNHL (grade ≥ 2b, requiring hearing aids)
at last evaluation (Table 1). All 33 patients received a CRD greater than 0 to both ears.
Patients with SNHL received RT at much younger ages than those with normal
hearing (median age, 3.2 v 7.8 years; P < .001; Figure 2). Patients with SNHL received a
higher CRD than those with normal hearing (median dose, 54.0 v 29.0 Gy; P < .001; Figure
3).

Figure 2. Number of patients with SNHL (Chang grade > 0) or normal hearing grouped by
age at initiation of RT (years) (N = 235). RT, radiation therapy; SNHL, sensorineural
hearing loss.
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Figure 3. Number of patients with SNHL (Chang grade > 0) or normal hearing grouped by
cochlear radiation dose (Gy), which refers to the higher cochlear dose that a patient received
between the left and right ears (N = 235). SNHL, sensorineural hearing loss.
Age at RT was inversely correlated with CRD to the left and right ears (Spearman r = –0.25
and –0.23, respectively; P < .001), indicating that younger patients received higher CRDs.
The majority of younger patients (age < 3 years) had infratentorial ependymoma (81.4%;
Fisher’s exact test P < .001). Left and right ear CRDs were correlated (Spearman r = 0.79; P
< .001), with no difference between left and right ears (P = .41). Of the 20 patients with
unilateral SNHL, 19 had SNHL in the ear that a received higher CRD (Figure 4).
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Figure 4. Scatter plot of cochlear radiation dose to the left and right ears of the 235
evaluable patients. Both, patients with bilateral sensorineural hearing loss (SNHL) (Chang
grade > 0) (n = 13); left, patients with unilateral SNHL (Chang grade > 0) in left ear (n =
14); normal, patients with normal hearing (n = 202); right, patients with unilateral SNHL
(Chang grade > 0) in right ear (n = 6).

Risk Factors Associated With RT-induced SNHL
In a multivariable model, age at RT and CRD were associated with higher odds of
SNHL. The odds of developing SNHL were 2.39 times higher for patients younger than 3
years at RT initiation (95% CI, 1.01 to 5.63, P = .05), with every Gy increase in CRD
estimated to increase the odds of SNHL by 7% (95% CI, 1.03 to 1.11; P < .001).
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SNHL Onset and Progression
For each patient with SNHL, we calculated the time from RT initiation to SNHL
onset (defined as Chang grade > 0 in either ear; Figure 5). For the 202 normal hearing

Figure 5. Overview of time from RT initiation to sensorineural hearing loss (SNHL) onset
(Chang grade > 0) and progression (an increase in Chang grade from SNHL onset to the
most recent evaluation). All 33 patients with SNHL were sorted by duration of follow-up.
Patients with shorter follow-up periods were placed on the left side of the plot, and those
with longer follow-up were placed on the right side. For all patients and ears in the plot, an
arbitrary 100 days were added to the last evaluation so that the Chang grade at last
evaluation can be visualized. L, left; R, right; RT, radiation therapy.

patients, the time variable was calculated from RT initiation to the latest audiologic
evaluation. The median time to SNHL onset was 3.6 years (range, 0.4 to 13.2 years). Two
patients experienced SNHL post-RT, one at 11.3 years and the other at 13.2 years. The error
(± SE) estimated SNHL-free survival at 5 years post-RT was 91% ±2.1% and at 10 years
was 84% ±3.7% (Figure 6). The median follow-up for those who did not experience SNHL
18

was 8.5 years (range, 0.8 to 16 years).

Figure 6. Kaplan-Meier plot showing the probability of not experiencing SNHL (Chang
grade > 0) after exposure to RT (N = 235). RT, radiation therapy; SNHL, sensorineural
hearing loss.

The majority of patients with SNHL (97.9%) participated in a follow-up evaluation
after SNHL onset; 19 (65.5%) experienced continued decline in hearing sensitivity, and 10
(34.5%) had no change. For patients with SNHL progression, the median time from SNHL
onset to increased Chang grade was 1 year (range, 0.4 to 5.6 years). Hearing loss progressed
within 3 years after onset in 17 patients and between 5 and 6 years in two patients. The
estimated probability of no progression at 5 years after SNHL onset was 35% ±11.6%
(Figure 7). Among 15 patients who had mild SNHL at onset, 14 had at least one follow-up
evaluation; 10 (71.4%) progressed to significant SNHL requiring hearing aids.
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Figure 7. Kaplan-Meier plot showing the probability of not experiencing progression of
hearing loss after SNHL onset (n = 33). RT, radiation therapy; SNHL, sensorineural hearing
loss.

Risk Factors Associated With Time to SNHL Onset
Based on a multivariable Cox model, younger age, higher CRD, and having a CSF
shunt were associated with higher risk of SNHL (Table 3). The hazard of SNHL was 2.3
times (95% CI, 1.21 to 4.46 times; P = .01) higher in patients younger than 3 years at RT
compared to those who were 3 years and older. Similarly, the hazard of SNHL increased
with higher CRD (HR, 1.1; 95% CI, 1.03 to 1.11; P < .001), and the hazard of SNHL in
patients with a CSF shunt was 2.0 times higher than were those without a shunt (95% CI,
1.07 to 3.78; P = .03).
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Table 3. Univariable and Multivariable Cox Proportional Hazards Models for Time to
Sensorineural Hearing Loss Onset

Univariable Model

Multivariable Model

HR

95% CI

P

HR

95% CI

P

Age at RT (years)

0.87

0.78-0.98

.0189

0.93

0.85-1.02

.1153

CRD (Gy)

1.08

1.04-1.12

< .001

1.07

1.04-1.11

.002

__

__

2.00

1.06-3.75

.0321

3.95

1.96-7.93

2.32

1.21-4.46

.0117

__

__

1.07

1.03-1.11

.003

Sex (male)

1.31

0.65-2.65

.4493

__

__

Shunt status (yes)

2.27

1.13-4.56

.0207

2.02

1.07-3.78

No. surgeries (> 1)

1.21

0.58-2.52

.6115

__

__

Variable
Continuous variable

Shunt status (yes)
Categorical variable
Age at RT (< 3 years)
CRD (Gy)

.001

.0290

__
__
Tumor location
3.47 1.63-7.38 .0012
(infratentorial)
Abbreviations: —, not applicable; CRD, cochlear radiation dose; HR, hazard ratio; RT,
radiation therapy.

Discussion
We prospectively and longitudinally examined hearing sensitivity and associated
risk factors for SNHL in pediatric patients treated with RT for brain tumors and found that
RT is associated with clinically significant SNHL in the absence of ototoxic chemotherapy.
Patients younger than 3 years at RT initiation, who have a CSF shunt, and who receive a
higher CRD are at greater risk. SNHL typically manifests about 3.5 years post-RT and
worsens over time. Because our study included frequent audiograms over long follow-up,
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we were able to identify delayed onset and progression of SNHL.
High-frequency SNHL can interfere with the acquisition of certain phonemes
(primarily fricatives) that are crucial for normal development and comprehension of speech
and language,28 especially if SNHL goes undetected and/or untreated. Even mild, atypical,
or unilateral hearing loss can impede communication and academic achievement. Children
with mild SNHL perform more poorly than their normal-hearing peers, and 37% repeat
grades; the normative rate for grade repetition is 3%.29 One study reported that 35% of
children with unilateral hearing loss failed at least one grade, and an additional 13%
required supplementary educational resources.37 Long-term childhood cancer survivors with
SNHL have declines in cognition,32 inferior academic performance,32,34 and overall poorer
self-reported quality of life.34 Early detection and treatment of SNHL results in better
outcomes for speech and language development, academic achievement, and social wellbeing.41-43
In the current study, we found 14% of children who received RT and no ototoxic
chemotherapy suffered SNHL. Williams et al.,13 however, observed a higher cumulative
SNHL incidence (27.4%) in a retrospective review of 100 children with brain tumors treated
with RT alone. This discrepancy is likely because the two studies used different criteria to
define SNHL. In Williams’ study, SNHL was defined as a 20 dB HL or more decrease in
either ear at 500, 1000, or 2000 Hz on a minimum of three audiograms, including one preRT baseline evaluation. Our study used the Chang Ototoxicity Grading Scale47 to calculate
the incidence and severity of SNHL because it is based on absolute-hearing thresholds and
has shown a strong correlation between ototoxicity grade and intervention/hearing aid
recommendation, increasing the relevance and clinical utility of our findings for clinicians
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who treat these patients. Although the Chang scale was developed to assess platinuminduced ototoxicity, it is also appropriate for radiation-induced ototoxicity given the
emphasis the criteria places on higher frequencies (i.e., higher frequencies are more severely
affected by platinum chemotherapy and RT) and particularly because it includes a criterion
(grade 2b) that specifies SNHL at any frequency below 4,000 Hz, which captures milder
degrees or atypical configurations (i.e., low or mid frequency) of SNHL that would not be
captured by other criteria such as the International Society of Pediatric Oncology (SIOP)
ototoxicity grading scale48 (Tables 4 and 5).

Table 4. The International Society of Pediatric Oncology (SIOP) Ototoxicity Grading Scale
Grade
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4

Criteria
≤ 20 dB HL at all frequencies
> 20 dB HL (i.e., ≥ 25 dB HL) SNHL above 4000 Hz (i.e., 6 or 8 kHz)
> 20 dB HL SNHL at 4000 Hz and above
> 20 dB HL SNHL at 2000 Hz or 3000 Hz and above
> 40 dB HL (i.e. ≥ 45 dB HL) SNHL at 2000 Hz and above

Table 5. Chang and SIOP Scores for Latest Audiologic Evaluation Per 10 Gy Dose
Threshold
Dose
Chang Score *
SIOP Score
Threshold
(Gy)
0
1
2
3
4
0
1
2
3
4
‡
0-10
27
1
1
27
1
11-20
34
34
21-30
48
2
48
2
31-40
33
1
33
1
41-50
28
1
1
4
28
1
3
2
> 50
32
2
2
6
12
32
4
2
6
10
Note: The worse ear was used when a patient had an asymmetric grade. *For comparison
purposes, Chang criteria were categorized as follows: Chang 0 = SIOP 0; Chang 1a = SIOP
1; Chang 1b, 2a = SIOP 2; Chang 2b = SIOP 3; Chang 3, 4 = SIOP 4. ‡This patient had
hearing loss (i.e. low frequency) that could not be defined by SIOP criteria.
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Of the 33 patients with SNHL, the majority (n = 28) had significant SNHL (grade ≥
2b) and required a hearing aid(s). Two other studies of SNHL in children who received RT
but not ototoxic chemotherapy reported severe SNHL23 and mild-to-moderate SNHL.4 In
both studies, SNHL was more severe for higher frequencies. High-frequency SNHL is
typical for patients with post-RT SNHL,4,13,23 which is consistent with our findings.
However, atypical SNHL patterns also occur: Nine of our patients had flat SNHL (similar
loss across all frequencies); two had tent-shaped SNHL (loss in the low and high
frequencies but normal in the mid- to high-frequency range), and two had U-shaped SNHL
(loss in the mid-frequency range with better hearing in the low and high frequencies).
The onset of SNHL post-RT varies across studies, occurring as early as 3 months49
and as late as 13 years. The median time to SNHL in our study was 3.6 years. This finding is
consistent with two previous studies in children who received RT; SNHL occurred at 18–36
months,23 and the mean time to onset was 49 months.13 Late onset of SNHL in children (i.e.,
after 5 years post-RT) was also documented in previous investigations.4,13
Previous studies of older children and adults receiving chemoradiation have shown
progressive SNHL.2,49,50 Likewise, most patients with SNHL in our study experienced
declining hearing during the first 3 years after SNHL onset. Nearly 75% of patients with
mild SNHL at diagnosis experienced hearing deterioration and eventually required hearing
aids.
Increased risk of post-RT SNHL in adults older than 50 years is well
documented.2,6,26,45 To our knowledge, the association of age with post-RT SNHL in
children has not been previously reported. Nevertheless, a lower mean CRD has been
recommended for children (< 35 Gy v. ≤ 45 Gy for adults)4,25-27 to minimize the risk of
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SNHL, suggesting that younger patients may be at higher risk for SNHL at RT doses
tolerated by adults. In our study, SNHL was twice as likely to occur in patients younger than
3 years. This was not surprising, as young age at the time of platinum-based chemotherapy
also increases a child’s risk for SNHL.51-54 Our study also indicated that infratentorial
ependymoma occurred more frequently in younger patients and the prescribed tumor dose
was higher for ependymoma; thus, younger patients were more likely to receive higher
CRDs.
Our study indicates that higher CRD and SNHL are associated, and several authors
have suggested a CRD threshold for pediatric patients. Fong et al.23 reported delayed, severe
SNHL in four children treated with 50 to 54 Gy and no chemotherapy. Merchant et al.3
recommended an average CRD of 32 Gy, over 6-weeks, to minimize risk of SNHL in
children. In a study of 78 children treated with RT alone, Hua et al.4 suggested a CRD
threshold of 35 to 45 Gy, with minimal risk of SNHL developing within 5 years post-RT at
CRDs less than 35 Gy. A Memorial Sloan-Kettering Cancer Center study55 revealed a 6%
rate of significant SNHL in 31 pediatric and adult patients treated with intensity-modulated
RT and adjuvant chemotherapy. In that study, a mean CRD of 38.6 ± 3.1 Gy was delivered
for patients receiving an 18-Gy dose of craniospinal irradiation (CSI) with a 54-Gy tumorbed boost, 40.6 ± 4.7 Gy for those receiving a 23-Gy dose of CSI with a 55.8- Gy tumor-bed
boost, and 49.1 ± 4.6 Gy for those receiving 36- or 39.6-Gy dose of CSI with a 55.8-Gy
tumor-bed boost; however, relatively short median follow-up (19 months) did not allow
detection of late-onset SNHL.
We also found an association between CSF shunting and risk of SNHL post-RT in
children. Guillaume et al.56 demonstrated an independent association between CSF shunting
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and SNHL in children receiving treatment for medulloblastoma. Our data support those
findings; subjects with a CSF shunt were twice as likely to have RT-induced SNHL. This is
not surprising; SNHL is a well-known complication of shunt placement for hydrocephalus
and other procedures resulting in loss of CSF.57-60 The etiology of SNHL after shunt
placement is not fully understood; however, changes in CSF pressure may alter cochlear
physiology.60,61 Excessive CSF drainage via a dilated cochlear aqueduct has been associated
with SNHL.61 Because children have a patent cochlear aqueduct, they may be at greater risk
for SNHL from shunt placements or other procedures that cause CSF pressure changes.61
Strengths of this study include a large sample size, radiation exposure, prospective
design, long-term follow-up, high-quality, standardized treatment, and ototoxicitymonitoring protocols. The limitation of this study is that it included only patients who had
adequate audiologic follow-up; SNHL data for patients who did not survive to participate,
who had insufficient audiologic evaluations, or who were lost to follow-up are not available
and may have differed from that of participants. Also, follow-up periods varied substantially
from 0.8 to 16 years. Some patients with brief follow-up may have had late-onset SNHL
that was missed.
Hearing loss is a serious health concern, particularly for children. Thus, children
who receive RT need long-term audiologic follow-up to help mitigate the negative
consequences of hearing loss. We recommend audiologic follow-up every 6 months for the
first 5 years post-RT and then annually thereafter for at least 5 additional years. In addition,
prospective trials of advanced RT approaches should include long-term audiologic followup to determine whether hearing is preserved by such modalities.
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Chapter 3
Auditory Outcomes in Patients Who Received
Proton Radiotherapy for Craniopharyngioma
Introduction
Pediatric craniopharyngioma is a rare, localized, histologically benign
neuroepithelial brain tumor that arises near the pituitary gland and hypothalamus during
embryonic development. Although craniopharyngioma is noncancerous and the 5- and 10year survival rates are higher than 90%,62 morbidity from the tumor and treatment is
substantial. Because craniopharyngioma develops within close proximity to neural
structures, namely the pituitary gland, hypothalamus, and optic pathways, the effects from
surgery, irradiation, and the tumor itself can lead to impaired cognition,63 vision,64-66 and
endocrine function.67-71 The current therapeutic approach for managing craniopharyngioma
includes a maximal tumor resection or partial tumor resection followed by radiotherapy.
Methods of irradiation have evolved over the past four decades with advances in
radiation physics and computer technology leading to greater precision of radiation delivery,
dose reduction to normal tissues, and less adverse effects. Conventional 3-dimensional
methods of photon-based radiotherapy have historically been used to treat a variety of
pediatric brain tumors, including craniopharyngioma; however, photon radiotherapy is
associated with severe late effects such as sensorineural hearing loss (SNHL). Incidence of
SNHL has been reported in 14% to 27% of children treated with photon radiotherapy and no
ototoxic chemotherapy.4,13,72
Proton radiotherapy (PRT) is an advanced method of irradiation currently being used
for the management of childhood cancer. While photon- and proton-based radiation
techniques offer similar tumor control,73 protons enable a reduction in dose delivery
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allowing for increased sparing of normal surrounding tissues and potentially reducing acute
and late toxicities when compared to photons.74 Recent studies have demonstrated decreased
incidence of SNHL in pediatric patients treated with PRT versus photon radiotherapy for
medulloblastoma16,17 and ependymoma.18
The traditional assessment for monitoring ototoxicity is measuring pure-tone
thresholds within the conventional frequency (CF) range from 0.25 through 8.0 kHz;
frequencies that are critical for speech and language acquisition and recognition. Extended
high-frequency (EHF) audiometry is the measurement of pure-tone thresholds at frequencies
9.0 through 20.0 kHz. In addition, distortion-product otoacoustic emissions (DPOAEs) are
typically used for monitoring ototoxicity, as these measurements are acquired objectively
and provide site-specific information regarding the integrity of the outer hair cells within the
cochlea. DPOAEs are low-level sounds emitted from spatially distributed regions within the
cochlea when acoustically stimulated. A decrease in DPOAE amplitude, decrease in signalto-noise ratio, and/or loss of DPOAE response indicate outer hair cell damage in the
cochlea.75
Radiation to the cochlea causes damage to the cochlear hair cells and surrounding
structures including the basilar membrane, spiral ligament, stria vascularis, spiral ganglion,
and cochlear nerve.19,20 Hair cell destruction typically occurs at the base of the cochlea
where high frequencies are encoded resulting in high-frequency SNHL.4,13,23,72 Similarly,
platinum-based chemotherapy agents (i.e., cisplatin and carboplatin) also damage cochlear
outer hair cell function,76-79 with more severe SNHL occurring in the high frequencies.52,78
Studies in patients treated with platinum chemotherapies have demonstrated that EHF
audiometry and DPOAEs detect evidence of ototoxicity sooner than CF audiometry,
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potentially serving as a predictor to ototoxic effects before damage occurs in frequencies
important for speech and language perception.80-84
Speech-in-noise (SIN) testing is used to assess the functional impact of ototoxicity
by evaluating the patient’s ability to comprehend speech (i.e., monosyllabic words or
sentences) in the presence of background noise. In a study by Einarsson et al,85 patients with
cisplatin-induced SNHL had significant difficulty understanding words in noise, scoring as
low as 54% below reference scores for subjects matched for age and degree of SNHL.
Based on these findings, one could hypothesize that 1) post-radiation hearing
sensitivity in the EHF range would be affected initially and potentially more severely than
hearing in the CF range, 2) DPOAEs would exhibit cochlear hair cell damage before SNHL
appeared in the CF range, and 3) SIN perception would decline from baseline measures. To
our knowledge, EHF audiometry, DPOAE, and SIN outcomes have not been previously
reported in patients treated with cranial radiotherapy alone. The objectives of this study
were to report the incidence, onset, and severity of ototoxicity; describe changes in hearing
and cochlear function by comparing DPOAE levels, CF pure-tone audiometric thresholds,
and EHF pure-tone audiometric thresholds over time; explore the potential impact PRT has
on SIN perception; and identify potential risk factors associated with decreased auditory
function in children and adolescents treated with PRT for craniopharyngioma.
Methods
Patients
Between 2011 and 2016, 112 children were enrolled in a multi-institutional, phase II
trial of radical surgery or limited surgery and PRT for craniopharyngioma. Patients between
the ages of 0 and 21 years were eligible for enrollment. Craniopharyngioma was diagnosed
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by histology, cytology, or neuroimaging. Patients received no radiation therapy or
potentially ototoxic drugs before enrollment. The trial (ClinicalTrials.gov Identifier:
NCT01419067) was approved by the Human Subjects Institutional Review Board at St.
Jude Children’s Research Hospital, and informed consent and assent were obtained from all
patients/guardians. All audiological evaluations were conducted at St. Jude Children’s
Research Hospital.
Patients underwent either a gross total resection and observation or sub-total
resection and PRT. For patients who received PRT, the total prescribed dose for the
planning target volume, that contained gross tumor volume plus margins for microscopic
diseases and setup uncertainty, was 5400 Cobalt centiGray Equivalent (CcGE) (i.e. 4909
cGy ×1.1 relative biologic effectiveness) administered at 180 CcGE per fraction with one
fraction per day, 5 fractions a week, for a period of 6 weeks. Each cochlea was contoured on
two consecutive CT images as a circular structure within the temporal bone. Because of the
small size, mean dose was calculated to represent the cochlear radiation dose (CRD). During
treatment planning, efforts were made to spare the cochlea without jeopardizing tumor
coverage. Exclusion criteria included patients not at risk for SNHL with a zero CRD (n=6),
patients with abnormal middle ear function (n=4), patients with insufficient audiologic data
(i.e., fewer than two evaluations or incomplete testing due to young age [n=14]), and
patients taken off study (n=14).
Audiologic Evaluations
Audiologic evaluations included otoscopy, tympanometry, pure-tone audiometry,
DPOAEs, and SIN testing. Otoscopy and tympanometry were used to assess the integrity of
the external ear canal, tympanic membrane, and middle-ear space. Pure-tone audiometry
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was assessed via conditioned play or conventional audiometry, depending on the child’s
age, development, cognition, and/or medical status. Pure-tone air-conduction thresholds
were measured in decibel hearing level (dB HL) under headphones in a sound-treated booth
at CFs of 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, and 8.0 kHz. EHF audiometry was evaluated at
9.0, 10.0, 11.2, 12.5, 14.0, and 16.0 kHz in children aged ≥ 5 years.86 Pure-tone boneconduction thresholds were assessed in dB HL at 0.25, 0.5, 1.0, 2.0, 3.0, and 4.0 kHz to
establish type of hearing loss (i.e., conductive, sensorineural, or mixed).
DPOAEs were measured at the frequency 2f1-f2 at f2 frequencies of 1.5, 2.0, 3.0, 4.0,
6.0, and 8.0 kHz with L1 = 65 dB sound pressure level (SPL), L2 = 55 dB SPL, and f2/f1 =
1.22. SIN testing was administered to English-speaking patients aged ≥ 5 years. The Quick
Speech-in-Noise (QuickSIN) test87 was administered to patients older than 14 years and the
Bamford-Kowal-Bench Speech-in-Noise (BKB-SIN) test88 was used for patients aged 5-14
years and for adolescents for whom the QuickSIN test was too difficult.
Determination of Ototoxicity
Audiologic evaluations were conducted by a certified, licensed audiologist prior to
PRT (baseline) and annually thereafter. Audiologic data were reviewed and ototoxicity was
determined by the first author (JKB). For this study, ototoxicity was assessed using two
different criteria. Clinically relevant SNHL was determined by assigning an ototoxicity
grade based on the Chang Ototoxicity Grading Scale47 (Table 6). The Chang ototoxicity
criteria consists of five levels of SNHL severity, ranging from grade 0 (no complications) to
grade 4 (severe complications), and utilizes absolute hearing threshold levels highly
correlated with recommendations for audiologic intervention (i.e., hearing aids, personal
frequency-modulation systems). Although initially developed to assess platinum-induced
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ototoxicity, the Chang ototoxicity scale has been used to rate radiation-induced ototoxicity,
particularly since it emphasizes hearing loss in the higher frequencies (i.e., higher
frequencies are more severely affected by radiotherapy) and it includes a criterion (grade 2b)
that captures milder degrees or atypical configurations (i.e., low- or mid-frequency) of
radiation-induced SNHL.
Table 6. Chang Ototoxicity Grading Scale
Grade

Criteria

0

≤20 dB at 1, 2, and 4 kHz

1a

≥40 dB at 6–12 kHz

1b

>20 and <40 dB at 4 kHz

2a

≥40 dB at ≥4 kHz

2b

>20 and <40 dB at <4 kHz

3

≥40 dB at ≥2 kHz

4

≥40 dB at ≥1 kHz

Note: Sensorineural hearing threshold was assessed by bone conduction or air conduction
with normal tympanogram. The worse ear was used when a patient had an asymmetric
Chang grade. Abbreviations: kHz, kilohertz; dB, decibel

A decline in hearing sensitivity--not clinically relevant SNHL per se-- for pure-tone
thresholds (0.25 to 16.0 kHz) was defined by the American Speech-Language-Hearing
Association (ASHA) criteria.89 The ASHA criteria identify a change (i.e., decrease) in
hearing sensitivity when compared to baseline measures as follows: 1) ≥ 20 dB HL decrease
in pure-tone threshold at a single test frequency, 2) ≥ 10 dB HL decrease in threshold at two
adjacent frequencies, or 3) loss of response at three consecutive frequencies where responses
were previously obtained. The ASHA criteria are not frequency specific and are used as a
binary outcome (yes or no) measure designed to detect early ototoxic changes before clinical
SNHL occurs. Results from the most recent evaluation were compared to baseline measures
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to evaluate ototoxicity using both the Chang scale and ASHA criteria. For cases of
asymmetrical SNHL, the worse ear was used when determining degree of ototoxicity.
A baseline DPOAE response was considered valid when the DPOAE amplitude
exceeded the mean level of the noise floor by ≥ 6 dB at each f2 frequency. In addition, at any
time point, the following three conditions were met for amplitude to be considered a valid
response: 1) normal middle ear function, 2) primary tone-level L1 value of 65 dB SPL ±2
dB, and 3) primary tone-level L2 value of 55 dB SPL ±2 dB. If any of these conditions were
not met, the response was excluded from the analysis. No universal criterion for significant
change in DPOAE level exists. For this study, the criterion for ototoxic change was defined
as a decrease in DPOAE amplitude ≥ 6 dB at one or more f2 frequencies based on previous
work by Bhagat83, who utilized a ≥ 6 dB criterion to determine an ototoxic change in
DPOAE amplitude in children treated with carboplatin for retinoblastoma.
The critical difference for comparing two conditions provided in the QuickSIN and
BKB-SIN test manuals was used to determine a significant clinical change between SIN test
scores. To familiarize the patient to the task, one list of five sentences was administered as a
practice list at 70 dB HL under headphones in both ears simultaneously. One list pair (i.e.,
two lists totaling 10 sentences) was then administered, and an average score was calculated
according to the scoring guidelines provided in the test manuals. The list pair score was
compared to the age-related norms to determine signal-to-noise ratio loss. The ageappropriate Wechsler Intelligence Scale was administered at baseline to derive a Full-Scale
IQ (FSIQ), or working memory index score if FSIQ was unavailable, for each patient. The
Wechsler Intelligence Scale for Children, 4th edition,90 was completed by the majority of
patients aged 6 to 16 years. The normative value of these scores was 100, with a standard
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deviation of 15. These data were used in this study to describe global cognitive function in
patients who completed SIN testing. Patients with an FSIQ score < 85 were excluded from
the SIN analysis.
Statistical Methods
Descriptive statistics were used to summarize patient demographics and clinical
characteristics. The McNemar’s exact test was used to compare hearing decline in the EHF
range (9.0-16.0 kHz) versus the CF range (0.25-8.0 kHz). The non-parametric McNemar’s
exact test is a repeated measures version of a Chi-square test of independence. The
McNemar test does not test for independence; rather, it evaluates consistency in responses
across two variables. The assumption of the Chi-square test is that the samples are taken
independently or are unpaired. Our data from the two groups came from the same
participants (i.e., our data were paired) so the McNemar’s test was more appropriate than the
Chi-square test.
The Kaplan-Meier curve and estimate was used to describe time to onset of
decreased hearing sensitivity. A univariable generalized estimating equation model with
repeated measures was used to investigate potential risk factors associated with decreased
hearing sensitivity. Potential explanatory variables included age at PRT initiation (years),
CRD (CcGE), gender, and race (white vs. non-white).
For DPOAE amplitude data analysis, mixed models for longitudinal data (i.e.,
random coefficient models) were used. A base model was initially built including time and
ear. For each patient, the first DPOAE test date was counted as day 1. For each follow-up
DPOAE evaluation, the time variable was counted as the days from the first DPOAE date.
We started from a full model, which included all covariates of interest: age at PRT
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initiation, CRD, gender, and race. Then we applied backward elimination, until all variables
that remained in the model were significant at the 0.05 level. This process was repeated for
12 datasets including the right and left ear responses at frequencies 1.5, 2.0, 3.0, 4.0, 6.0,
and 8.0 kHz. A random coefficient model was used to examine SIN performance over time.
The definition and derivation of the time variable in this model was equivalent to the one
used in the DPOAE analysis. A significance threshold of 0.05 was used throughout without
adjusting for multiplicity.
To address the concern that selection bias may have affected our results, we
compared demographic and treatment characteristics between participants and nonparticipants using the Fisher’s exact tests and the Wilcoxon-Mann-Whitney tests as
appropriate. Analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) and R 3.3.0
(R Core Development Team; http://www.r-project.org/).
Results
Patient Characteristics
Table 7 provides demographic and clinical characteristics of the 74 evaluable
patients. Median age at PRT initiation was 10 years (range, 4 to 19.3 years), and median
CRDs to the left and right ears were 126 CcGE (range, 0.2 to 5449 CcGE) and 143 CcGE
(range, 0.2 to 5215 CcGE), respectively. The median follow-up from PRT initiation to latest
audiogram was 2 years (range, 0.7 to 5.2 years).
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Table 7. Patient Characteristics (N = 74)
Characteristic
Sex
Male
Female
Race
White
Non-white
Shunt status
Yes
No
Age at initiation of PRT
(years)
Age at latest audiogram
(years)
Time from initiation of PRT
to latest audiogram (years)
Left ear CRD (CcGE)

No (%)

Median

Range

Interquartile
Range

10

4, 19.3

7.7, 13.9

12.5

5, 24.3

9.9, 15.6

2

0.7, 5.2

1, 3.1

126

0.2, 5449

11, 979

143

0.2, 5215

9, 518

35 (47.3%)
39 (52.7%)
49 (66.2%)
25 (33.8%)
5 (6.8%)
69 (93.2%)

Right ear CRD (CcGE)

Abbreviations: CRD, cochlear radiation dose; CcGE, Cobalt centiGray Equivalent; No.,
number of; PRT, proton radiotherapy

Ototoxicity Based on the Chang Ototoxicity Grading Scale
No patients had clinically relevant SNHL in the CF range. Among the 74 evaluable
patients, two (2.7%) had Chang grade > 0 at last evaluation for the EHF range only. One
patient had unilateral Chang grade 1a at frequencies ≥ 10 kHz and the other patient had
bilateral moderate Chang grade 1a at frequencies ≥ 10 kHz for the right ear and ≥ 9 kHz for
the left ear. The severity of SNHL fell within the moderate to moderately-severe range for
the patient with unilateral loss and moderate range for the patient with bilateral loss.
Ototoxicity Based on the ASHA Criteria
Based on the ASHA criteria at last evaluation, a decrease in hearing sensitivity was
observed in 24 (32.4%) patients in CF and/or EHF ranges; 11 patients had unilateral
decrease and 13 patients had bilateral decrease when compared to baseline measures.
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Patients who met the ASHA criteria for decreased hearing were more likely to experience a
decline in the EHF range compared to the CF range (McNemar’s test exact P = 0.0039)
(Figure 8).
14

Right Ear

Left ear

Number of Ears

12
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8
6
4
2
0
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11.2 12.5

14

16

Figure 8. Number of right and left ears with decreased hearing sensitivity as defined by the
American Speech-Language-Hearing Association (ASHA) criteria as a function of
frequency. N = 37 ears; 11 patients with unilateral hearing loss and 13 patients with bilateral
hearing loss.
For each patient who met the ASHA criteria, the onset of decreased hearing was
defined as the time from PRT initiation to the date when a patient first met the ASHA
criteria in either ear. The median time to onset of decreased hearing was 24.6 months (range:
11.1 to 63.4 months), and the estimated probability of not having decreased hearing
sensitivity at the end of 3 years post-PRT was 70% ±7.4% and 38% ±15% at 5 years (Figure
9).
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Figure 9. Kaplan- Meier plot of time-to-onset of decreased hearing by the American
Speech-Language-Hearing Association (ASHA) criteria. For each of the 24 patients who
met ASHA criteria, the time variable was calculated from the date of proton radiotherapy
(PRT) initiation to the date when a patient first met the ASHA criteria in any ear. For each
of the 50 patients without decreased hearing, the time variable was calculated from the date
of PRT initiation to the date of last audiology evaluation.
Risk Factors Associated with Hearing Decrease by ASHA Criteria
Of the 148 ears from 74 evaluable patients, five ears were not included in the
analysis due to abnormal middle-ear function at either baseline or last audiologic evaluation.
Of the remaining 143 ears included in the analysis, 37 ears from 24 patients met the ASHA
criteria for decreased hearing sensitivity. In a univariable model, older age at PRT initiation
was the only risk factor associated with a decline in hearing sensitivity (Table 8). The odds
ratio for developing a decrease in hearing was estimated to be 1.2 for every one-year
increase in age at PRT initiation (95% confidence interval: 1.03, 1.31, P = 0.0114).
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Table 8. Univariable generalized estimating equation model for potential risk factors
associated with decreased hearing sensitivity
Variable

OR

95% CI

P

Age at PRT
(years)

1.165

1.035, 1.311

0.0114

Race (white)

0.918

0.337, 2.50

0.8674

Sex (male)

0.689

0.266, 1.787

0.4441

CRD (Gy)

0.990

0.935, 1.047

0.7146

Abbreviations: OR, odds ratio; CI, confidence interval; P, p-value; PRT, proton
radiotherapy; CRD, cochlear radiation dose; Gy, Gray
DPOAEs
For the analysis of DPOAE amplitude, 12 datasets were analyzed based on the
combinations of right and left ears at different frequencies 1.5, 2.0, 3.0, 4.0, 6.0, and 8.0
kHz. The number of patients with valid DPOAE measurements varied from 40 to 69
patients depending on the test frequency. In all 12 datasets, amplitude reduction was
observed at varied rates. DPOAE amplitude decreased at a much faster rate at higher
frequencies (including 6 and 8 kHz) than at lower frequencies, and older age at PRT
initiation was associated with decreased amplitude at 3.0, 4.0, and 6.0 kHz (P = 0.0127, P =
0.0283; P = 0.0002, respectively) (Table 9). Figure 10 illustrates the decrease in mean
DPOAE amplitude averaged across both ears for f2 frequencies at baseline and most recent
evaluations.
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Table 9. Mixed model analyses of DPOAE amplitude over time
Frequency
(kHz)

No (%)
patients*

Effect

Estimate

95% CI of the
Estimate

P

1.5

67 (91)

Time (years)

-0.7009

-1.1636, -0.2382

0.0035

2

69 (93)

Time (years)

-0.8760

-1.2476, -0.5044

<.0001

3

66 (89)

Time (years)

-0.7789

-1.1568, -0.4010

0.0001

Age at PRT
initiation (years)

-0.4053

-0.7208, -0.0898

0.0127

Time (years)

-0.5843

-1.1220, -0.0466

0.0346

Age at PRT
initiation (years)

-0.4080

-0.7712, -0.0448

0.0283

Time (years)

-2.0530

-2.7659, -1.3401

<.0001

Age at PRT
initiation (years)

-0.7223

-1.0931, -0.3515

0.0002

Time (years)

-1.6543

-2.6367, -0.6719

0.0017

4

6

8

63 (85)

59 (80)

40 (54)

*Percentage was calculated using 74 evaluable patients. Abbreviations: DPOAE, distortion
product otoacoustic emission; kHz, kilohertz; No., number of; CI, confidence interval; P, pvalue; PRT, proton radiotherapy

40

Figure 10. Mean distortion-product otoacoustic emission (DPOAE) amplitudes collapsed
across ears at baseline and last evaluations plotted as a function of f2 frequency. Only data
from ears with valid DPOAEs were included in mean calculations. Abbreviations: Hz,
Hertz; SD, standard deviation.

On an individual patient basis, criterion reductions (≥ 6 dB decrease between
baseline and most recent evaluation) in DPOAE levels were also observed with a higher
percentage of ears having a decrease in the higher frequencies (Table 10).
Table 10. Number of ears that met criterion reduction for decreased DPOAE amplitude
No
No (%)
No
No (%)
Eligible
Right Ear ≥ 6 dB
Eligible
Left Ear ≥ 6
Right Ears
Reduction
Left Ears
dB Reduction
1.5
60
11 (18.3)
60
11 (18.3)
2
64
11 (17.2)
59
10 (16.9)
3
65
18 (27.7)
59
16 (27.1)
4
65
18 (27.7)
64
18 (28.1)
6
65
20 (30.8)
63
29 (46)
8
35
14 (40)
31
14 (45.2)
Abbreviations: DPOAE, distortion product otoacoustic emission; kHz, kilohertz; No.,
number of; dB, decibel
Frequency
(kHz)
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Speech-in-Noise Perception
Of 74 evaluable patients, 26 patients were excluded from this analysis based on
missing or incomplete SIN data (n = 15) and a baseline IQ score < 85 (n = 11). Of the 48
evaluable patients, 41 were administered the BKB-SIN test and 7 were administered the
QuickSIN test. Due to small sample size, statistical analysis could not be performed on
patients evaluated with the QuickSIN test. For the 41 patients evaluated using the BKB-SIN
test, SIN perception did not decline over time (P = 0.646).
Participants versus Non-participants
No difference was observed for gender (Fisher’s exact test P = 0.8431), race
(Fisher’s exact test P = 0.6774), shunt status (Fisher’s exact test P = 0.4853), time from
initiation of PRT to latest audiogram (Wilcoxon-Mann-Whitney test P = 0.1393), or right
ear CRD (Wilcoxon-Mann-Whitney test P = 0.1929). Participants were, however, older at
initiation of PRT (Wilcoxon-Mann-Whitney test P = 0.0001) and at latest audiogram
(Wilcoxon-Mann-Whitney test P < 0.001), and received higher left ear CRDs (WilcoxonMann-Whitney test P = 0.0458) when compared to non-participants.
Discussion
Changes in auditory function were prospectively and longitudinally evaluated via
CF and EHF audiometry in 74 patients treated with PRT for childhood craniopharyngioma.
At last evaluation, no patients experienced clinically relevant SNHL in the CF range as
defined by the Chang ototoxicity scale, and SIN performance did not decline over time.
However, almost one-third of patients experienced a decrease in hearing sensitivity
according to the ASHA criteria in either or both the CF and EHF ranges when compared to
baseline measures. Hearing was more likely to decrease in the EHF compared to the CF
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range, and DPOAE amplitude decreased at a faster rate for higher frequencies compared to
lower frequencies. Additionally, older age at start of PRT was associated with decreased
hearing sensitivity and DPOAE amplitude.
Previous studies in children treated with photon radiotherapy to the head and neck
in the absence of chemotherapy have reported SNHL as a late adverse effect. In a study by
Williams et al,13 radiation-induced SNHL, defined by a 20-dB decrease in hearing from
baseline measures at frequencies 250 to 8000 Hz, was observed in 27% of children. Hua et
al4 reported SNHL following cranial radiation in 14% of patients, where SNHL was defined
as thresholds greater than 25 dB on at least two consecutive audiological evaluations with
no return to normal hearing on subsequent evaluations. Bass et al72 used the Chang
ototoxicity grading scale to report SNHL in a cohort of pediatric patients treated with
conventional radiation for brain tumors and observed a 14% incidence of SNHL. In the
current series, we reported a lower prevalence of SNHL following PRT with only 2.7% (n =
2) of children experiencing a Chang grade 1a in the EHF range only. Studies on normative
thresholds have shown that mean EHF thresholds for school-aged children fell below 15 dB
HL, comparable to CF thresholds,91 and that hearing sensitivity begins to decline in the EHF
of 15-18 kHz at approximately 20 years of age.92 Thus, age did not contribute to decreased
hearing in our study cohort. Although a change in hearing sensitivity using the ASHA
criteria was observed in the CF range in 15 patients, all thresholds were < 25 dB which was
not considered to be clinically relevant SNHL. Our findings are consistent with other studies
that have shown a reduced incidence of SNHL in pediatric patients treated with PRT for
medulloblastoma16,17 and ependymoma.18
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One explanation for the lower prevalence of radiation-induced SNHL observed in
our study sample is overall lower radiation exposure to the cochlea, which may be attributed
to the use of PRT. The median CRD for our sample was 126 and 143 CcGE for the left and
right ears, respectively, compared to higher CRDs reported in previous studies, for example,
a median CRD of 29.5 Grey (Gy) for the left ear and 28.8 Gy for the right ear reported by
Bass et al,72 a mean CRD of 34.8 Gy between ears reported by Hua et al,4 and a median
CRD of 54 Gy between ears reported by Williams et al.13 These studies have also
demonstrated that patients exposed to higher CRDs are more likely to develop SNHL. In our
study, CRD was not associated with decreased hearing sensitivity (P = 0.7146); however,
majority of the patients in our cohort received low CRDs (i.e., less than 2000 CcGE as seen
in Table 11) limiting our analysis of a potential dose effect.
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Table 11. Number of patients who did or did not meet ASHA criteria for decreased hearing
at last evaluation according to CRD
Met ASHA criteria for decreased hearing at last evaluation
No

Yes

Total

n

%

n

%

N

0 - 25

13

61.9

8

38.1

21

25 <- 50

2

50.0

2

50.0

4

50 <- 75

2

40.0

3

60.0

5

75 <- 100

1

50.0

1

50.0

2

100 <- 1000

18

81.8

4

18.2

22

1000 <- 2000

9

81.8

2

18.2

11

2000 <- 3000

2

100.0

0

0.0

2

3000 <- 4000

2

66.7

1

33.3

3

4000 <- 5000

0

0.0

2

100.0

2

5000 <- 6000

1

50.0

1

50.0

2

CRD (CcGE)*

*Higher cochlear dose that a patient received between the left and right ears. Abbreviations:
ASHA, American Speech-Language-Hearing Association; N (n), number; CRD, cochlear
radiation dose; CcGE, Cobalt centiGray Equivalent

The median time to onset of decreased hearing per the ASHA criteria in our series
occurred at 24.6 months post-PRT, sooner than the median time to onset of 43.2 months72
and the mean time to onset of 49 months4 previously reported in children treated with
photon radiotherapy. The earlier time to onset of decreased hearing observed in our study is
likely due to use of the ASHA criteria, criteria that are used to measure a change in hearing
sensitivity, not clinically relevant SNHL. In addition, we measured EHF thresholds that are
likely to decline sooner than CF thresholds. Previous studies reported absolute hearing
threshold outcomes in the CF range only; changes in hearing sensitivity from baseline
measures for CF and EHF thresholds were not measured in previous reports. Our findings
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suggest that decreased hearing sensitivity occurs sooner in the EHF range than the CF range.
Other studies have drawn similar conclusions in patients undergoing ototoxicity monitoring
for cisplatin chemotherapy.82,83 Longer audiologic follow-up in our study cohort is needed
to determine if changes in the EHF range predicts subsequent CF hearing loss.
The DPOAE test is an objective measurement of cochlear function and can be
administered in conjunction with or as an alternative to behavioral audiometry in children
undergoing treatment for cancer. Studies have demonstrated that DPOAEs exhibit subtle
cochlear outer hair cell damage prior to hearing threshold shifts in the CF range.80-83
Likewise, patients in our study who experienced a decline in DPOAE amplitude did not
exhibit clinically relevant SNHL in the CF range, implying that DPOAEs can also detect
subtle cochlear damage before SNHL is identified in the CF range in children treated with
PRT. Additionally, our findings revealed that reductions in DPOAE amplitude occurred at a
much faster rate in the higher frequencies compared to the lower frequencies. This is not
surprising as other studies have demonstrated that radiation-induced SNHL is more severe
in the higher frequencies.13,23,72 Studies in children treated with platinum chemotherapy have
also found that DPOAE amplitude reductions are greater for the higher frequencies than the
lower frequencies.82,83 Whether or not clinically relevant SNHL will eventually develop in
our study patients remains unclear at this time; thus, long-term audiologic follow-up in
patients who receive PRT is warranted.
The association between age at initiation of photon radiotherapy and the
development of SNHL was previously reported in a study by Bass et al72 that showed
children younger than 3 years were twice as likely to develop SNHL compared to older
children. Conversely, data from the present study revealed that older children at initiation of
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PRT were 1.2 times more likely to experience decreased hearing sensitivity. Additionally,
older age at PRT initiation was also associated with reductions in DPOAE amplitude for the
higher frequencies 3, 4, and 6 kHz. The difference in age for the participants evaluated
between these two studies may explain the discrepancy in the findings, given that children
younger than 4 years were not included in the current study analysis. Also, the
measurements and criteria used to define ototoxicity differed across studies potentially
impacting the association between age and hearing loss.
In the current study, we did not observe a significant decline in SIN perception over
time among patients who were administered the BKB-SIN test. One study demonstrated that
patients with cisplatin-induced SNHL had poorer than expected perception of speech in the
presence of background noise;85 however, this is not surprising given the severe loss of
high-frequency hearing typically observed in patients treated with cisplatin. Although some
patients in our study experienced a decline in hearing sensitivity from baseline to last
evaluation, all patients’ hearing remained within the normal hearing range for the CFs—the
frequencies most important for speech perception.
The strengths of this research include prospective and comprehensive audiologic
evaluations and homogenous radiation exposure. Our findings, however, should be
considered with caution in light of study limitations. Follow-up time varied from 0.7 to 5.2
years, potentially missing late-onset changes in auditory function in patients with short
follow-up time. Only patients with sufficient audiologic baseline and follow-up data were
included in the analysis; thus, we performed statistical analyses to assess for potential
differences in demographic and treatment characteristics among participants and nonparticipants to rule out potential selection bias. The difference in age among participants and
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non-participants is likely due to the outcome measures used in the study. Extended high
frequency audiometry is unreliable in children younger than 5 years,86 and valid, reliable
DPOAE results require the child to be still and quiet during testing. As a result, EHF
audiometry and/or DPOAE testing could not be measured in some of the younger patients,
excluding them from the analysis. Future research is needed to determine appropriate
auditory testing methods and auditory outcome measures in younger children receiving
PRT. Every patient included in the analysis had at least > 0 CcGE CRD to either ear. If both
ears received 0 CcGE CRD, the patient was excluded from the analysis as s/he was not
considered at risk for SNHL. Some patients had 0 CcGE CRD to one ear and > 0 CcGE
CRD to the other ear and were included in the analysis. This imbalance of CRD between
ears may account for the difference observed in left ear CRDs between participants and nonparticipants.
In summary, auditory outcomes were favorable in patients treated with PRT.
Preservation of hearing within the CF frequency range critical for speech acquisition and
comprehension was maintained with no decline in SIN performance. Subtle decreases in
hearing sensitivity, particularly in the EHF range, and DPOAE amplitude were observed;
thus, EHF audiometry and DPOAE testing should be considered in the ototoxicity
monitoring protocol as they are more sensitive to initial effects of radiation therapy than is
conventional pure-tone audiometry. Long-term audiological follow-up is recommended to
monitor for potential late effects on hearing sensitivity.
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Chapter 4
General Conclusion
The two manuscripts in this dissertation examined the impact of cranial RT on
auditory function in patients treated for childhood cancer. Both studies were prospective in
design and implemented statistical models with repeated measures to investigate potential
risk factors associated with SNHL.
In the first manuscript, we found that SNHL was prevalent in 14% of patients treated
with conformal photon-based RT for childhood brain tumors. SNHL was considered a late
adverse effect of RT, occurring years post-RT. Hearing continued to worsen over time in the
majority of patients with nearly 75% requiring hearing aids. Additionally, we discovered
that younger age at RT initiation, higher CRD, and CSF shunting were associated with
SNHL. Sensorineural hearing loss was twice as likely to occur in patients younger than 3
years and in patients with a CSF shunt, and the odds of SNHL increased with higher CRDs.
Thus, long-term audiologic follow-up is recommended in children who receive conformal
photon-based RT for timely identification and management of SNHL.
In the second manuscript, auditory outcomes were examined in pediatric patients
treated with an advanced proton-based RT modality for craniopharyngioma. Because PRT
spares surrounding healthy tissue from radiation exposure, adverse effects, such as SNHL,
should be reduced. Indeed, our study revealed a prevalence of 2.7% for SNHL in patients
treated with PRT, which is significantly lower than the prevalence of SNHL reported in
previous studies in children treated with photon-based RT. Moreover, SNHL was only
observed in the EHF range while hearing remained within normal limits for the CFs for all
patients, and SIN perception did not decline following PRT. Although normal hearing

49

sensitivity was maintained within the CF range, sub-clinical deceases in hearing sensitivity
were observed. Decreased hearing was detected in either or both the CF and EHF ranges for
32.4% of patients, although hearing was more likely to decline in the EHF range compared
to the CF range. Reductions in DPOAE amplitude also occurred at a much faster rate in the
higher versus lower frequencies. Thus, EHF and DPOAE testing appear to be more sensitive
than CF pure-tone audiometry to detecting subtle changes in auditory function and may
detect decreased hearing sensitivity prior to SNHL occurring in the frequencies critical for
speech acquisition and perception. Our study also showed that older children at the start of
PRT were more likely to experience decreased hearing sensitivity and reduced DPOAE
amplitudes in the higher frequencies.
Collectively, these two studies demonstrate the importance of long-term audiologic
follow-up in children who receive either photon- or proton-based RT. Our findings suggest
that children treated with photon-based RT are more likely to experience SNHL and with
greater severity compared to children treated with proton-based RT, requiring routine, longterm audiologic follow-up. Improvements in RT modalities, such as PRT, have led to
reduced treatment-related effects. Overall, our findings support favorable auditory outcomes
in patients treated with PRT; however, long-term audiologic follow-up is still warranted as
sub-clinical changes in auditory function were observed in our cohort. Thus, EHF
audiometry and DPOAE testing should be considered in ototoxicity monitoring protocols as
they are more sensitive to initial effects of RT than conventional pure-tone audiometry.
Although our findings indicate that patients treated with PRT have improved
auditory outcomes, longer follow-up time is warranted to monitor for late onset of SNHL.
The median time from initiation of PRT to the latest audiological evaluation in our cohort
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was two years. Previous studies in children treated with photon RT were followed for a
longer period of time: Bass et al72 reported a median follow-up of nine years and Hua et al4
reported follow-up ranging from four to six years. Additionally, our study on PRT included
only patients diagnosed with craniopharyngioma and CRDs were, on average, lower due to
tumor location. Prospective, longitudinal studies in children treated with PRT for various
brain tumors and CRDs are needed to more thoroughly assess long-term auditory outcomes.
Nevertheless, we believe our findings will serve as an important reference for the fields of
radiation oncology and audiology as well as a benchmark to be used to further improve
radiation therapy modalities to reduce treatment-related SNHL.
Contributions to the Dissertation
I was the primary contributor in these two papers, designing the studies, collecting,
organizing, and interpreting data, interpreting statistical analyses, interpreting the results,
and writing the papers. My co-authors in both publications provided guidance and
feedback in study design and writing. Dr. Thomas Merchant in the Department of
Radiation Oncology was the primary investigator of the phase II clinical trials at St. Jude
Children’s Research Hospital. Dr. Daniel Indelicato in the Department of Radiation
Oncology at the University of Florida was a co-investigator on the phase II clinical trial
for patients treated with proton radiotherapy for craniopharyngioma. Jie Huang and Dr.
Arzu Onar-Thomas in the Department of Biostatistics at St. Jude Children’s Research
Hospital provided analytical support.
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